|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Descriptive Information Fields | |||||
| Brief Title † | Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy | ||||
| Official Title † | Profonycia - Honey for Improving Quality of Patient's Life Receiving Chemotherapy | ||||
| Brief Summary | Myelosuppression (bone marrow suppression) is the most important toxic side effect of the majority of chemotherapeutic agents and typically is the dose limiting factor. Death occurring after chemotherapy usually results either from infection related to drug induced leucopenia or from bleeding related to thrombocytopenia. Colony stimulating factors (CSFs) are widely used in the treatment of chemotherapy induced neutropenia. The same Erythropoetines are used in the treatment of chemotherapy induced anemia. Both treatments are expensive and have several side effects. In our previous stud (1) we found a special kind of honey: Life-Mel Honey to reduce the incidence of chemotherapy induced pancytopenia and improving quality of life. The aim of the recent planed study is to provide prophylactic and protective treatment against neutropenia reducing the need for secondary CSF administration in patients receiving chemotherapy along with a natural and non expensive honey: Profonycia. This honey which is expressed in Kibutz Shamir in Upper Galliee seems promising and easy for administration: given 5 gr/day per os for 7 days from the administration of chemotherapy. |
||||
| Detailed Description | |||||
| Study Phase | |||||
| Study Type † | Interventional | ||||
| Study Design † | Prevention, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study | ||||
| Primary Outcome Measure † | |||||
| Secondary Outcome Measure † | |||||
| Condition † | Myelosuppression | ||||
| Intervention † | Dietary Supplement: Profonycia | ||||
| MEDLINE PMIDs | 17303914 | ||||
| Links | |||||
| Recruitment Information Fields | |||||
| Recruitment Status † | Recruiting | ||||
| Enrollment † | 50 | ||||
| Start Date † | September 2007 | ||||
| Completion Date | |||||
| Eligibility Criteria † | Inclusion Criteria: Patients 18 years old or elder receiving chemotherapy 1/2-3 weeks Exclusion Criteria: Patients below 18 years old |
||||
| Gender | Both | ||||
| Ages | 18 Years to 80 Years | ||||
| Accepts Healthy Volunteers | No | ||||
| Contacts †† |
|
||||
| Location Countries † | Israel | ||||
| Administrative Information Fields | |||||
| NCT ID † | NCT00524797 | ||||
| Organization ID | HP 7-260 S | ||||
| Secondary IDs †† | |||||
| Study Sponsor † | Ziv Hospital | ||||
| Collaborators †† | |||||
| Investigators † |
|
||||
| Information Provided By | Ziv Hospital | ||||
| Verification Date | September 2007 | ||||
| First Received Date † | September 2, 2007 | ||||
| Last Updated Date | September 2, 2007 | ||||